Lazard Asset Management LLC Increases Stake in iRadimed Corporation $IRMD

Lazard Asset Management LLC increased its stake in iRadimed Corporation (NASDAQ:IRMD) by 15.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 48,914 shares of the medical equipment provider’s stock after acquiring an additional 6,524 shares during the period. Lazard Asset Management LLC owned approximately 0.38% of iRadimed worth $4,708,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Farther Finance Advisors LLC grew its position in iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 397 shares during the period. Quarry LP acquired a new stake in iRadimed during the third quarter worth about $40,000. CWM LLC raised its holdings in shares of iRadimed by 19.5% in the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after purchasing an additional 107 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the period. Finally, Global Retirement Partners LLC acquired a new position in shares of iRadimed in the 4th quarter valued at about $85,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $120.00.

Insider Activity

In other news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.60, for a total value of $226,500.00. Following the completion of the sale, the chief executive officer owned 2,162,500 shares in the company, valued at approximately $195,922,500. This trade represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,250 shares of company stock valued at $1,836,403 in the last ninety days. 34.60% of the stock is currently owned by company insiders.

iRadimed News Roundup

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

iRadimed Trading Down 4.6%

NASDAQ:IRMD opened at $90.86 on Friday. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of 49.65 and a beta of 0.90. The firm’s fifty day simple moving average is $94.54 and its 200 day simple moving average is $95.70. iRadimed Corporation has a twelve month low of $57.83 and a twelve month high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The firm had revenue of $20.47 million during the quarter, compared to analysts’ expectations of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts predict that iRadimed Corporation will post 1.52 earnings per share for the current year.

iRadimed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be given a $0.20 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. iRadimed’s dividend payout ratio is presently 43.72%.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.